较低剂量的尼沃卢马布和伊皮利穆马布改善了晚期黑色素瘤患者的治疗结果,并减少了副作用. Lower-dose nivolumab and ipilimumab improved outcomes and reduced side effects in advanced melanoma patients.

卡罗林斯卡研究所的一项新研究发现,使用尼沃卢马布和伊皮利穆马布的低剂量免疫疗法方案,与标准高剂量相比,改善了晚期黑色素瘤患者的结果. A new study from Karolinska Institutet finds that a lower-dose immunotherapy regimen using nivolumab and ipilimumab improved outcomes for advanced melanoma patients compared to standard higher doses. 在近400名参与者中,低剂量组的回复率为49%,连续九个月的无进展生存期和总体生存期为42个月,其表现优于较高剂量组。 Among nearly 400 participants, the lower-dose group had a 49% response rate, nine months of progression-free survival, and 42 months of overall survival, outperforming the higher-dose group. 严重副作用也较低,31%的病人患有严重副作用,而51%的病人患有严重副作用。 Serious side effects were also lower, occurring in 31% versus 51% of patients. 研究结果表明,尽管研究是观察性的,无法证实因果关系,但治疗容忍度和持续治疗都有所提高。 The results suggest better treatment tolerance and sustained therapy, though the study was observational and cannot confirm causation. 研究人员说,研究结果可能会为今后的剂量战略提供参考。 Researchers say the findings may inform future dosing strategies.